Tandem Diabetes Care Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Hi, everyone. This is Steve Lichtman, medical devices analyst at Oppenheimer. Welcome to the 31st Annual Oppenheimer Healthcare Conference. Very happy to have with us up next Tandem Diabetes Care. With us today is John Sheridan, President and CEO; and Leigh Vosseller, Executive Vice President and Chief Financial Officer. We will have a few slides up here upfront, and then we'll go into Q&A. If you do have a question, please key them in, and I'll get them right over to John and Leigh.
With that, I'm going to turn the podium over to John.
Thanks, Steve. It's great to see you. And good morning, everybody. I'll just start off by saying that 2020 was a remarkable year for Tandem. We nearly eclipsed $500 million in sales. We launched Control-IQ, which is clearly the most advanced commercially available automated insulin delivery system. We have over 200,000 people using Tandem's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
